Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
Clinical trial NCT07393373 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07393373
- Sponsor
- QED Therapeutics, a BridgeBio company
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-23
- Primary completion
- 2036-05-31
- Enrollment
- 135
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.